Tradestie Institutional Equity Comparison Engine
VIVS vs NVCT โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
NVCT Overall Edge
NVCT Captures Institutional Edge (3โ0 Pillars ยท 7โ0 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Nuvectis Pharma, Inc. Common Stock (NVCT) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, VIVS trades at N/M Forward P/E with -10117.0% operating margin (-51.4% YoY revenue) versus NVCT at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, VIVS sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro) against NVCT sits in BREAKDOWN (17th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
VIVS N/M vs NVCT N/M Fwd P/E
Growth & Margin Winner
NVCT
Op Margin -10117.0% vs 0.0% ยท YoY -51.4% vs +0.0%
Momentum & Technical Winner
NVCT
1Y -87.0% vs +227.9% ยท 52W Pos 5% vs 60%
Options & Structure Winner
NVCT
BREAKDOWN (N/A IV) vs BREAKDOWN (17th %ile IV)
VIVS
NASDAQ
VivoSim Labs, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$0.29
+142.92% 1D
Market Cap
$2.4M
1M Return
+64.69%
1Y Return
-86.99%
Forward P/E
N/M
Unified AI Score
36.8 / 100
SELL
Tech 5.0
Fund 38.0
Flow 50.0
Mom 50.0
NVCT
NASDAQ
Nuvectis Pharma, Inc. Common Stock
Pharmaceutical Preparations
$19.84
-2.22% 1D
Market Cap
$697.8M
1M Return
-4.15%
1Y Return
+227.93%
Forward P/E
N/M
Unified AI Score
45.1 / 100
HOLD
Tech 31.0
Fund 50.0
Flow 68.0
Mom 50.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
VIVS -86.99%
NVCT +227.93%
Spread: +314.92 pp (NVCT Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
VIVS TTM Op. Margin: -10117.0%
NVCT TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on VIVS vs NVCT. Trailing 12-month operating profitability (VIVS -10117.0% vs NVCT 0.0%) and valuation multiples (VIVS N/M vs NVCT N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | VIVS | NVCT | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $2.4M | $697.8M | Larger Scale | NVCT |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | -51.4% | +0.0% | Higher Growth | NVCT |
| Operating Margin (TTM) Profitability | -10117.0% | 0.0% | Higher Margin | NVCT |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -343.1% | -67.0% | Higher ROE | NVCT |
| 52-Week Range Position Momentum | 5% ($0โ$3) | 60% ($6โ$29) | Stronger Trend | NVCT |
| Beta / 30D Volatility Risk Regime | 0.83ฮฒ ยท 480% Vol | 0.67ฮฒ ยท 79% Vol | Lower Realized Risk | NVCT |
| Unified Institutional Score Composite Signal | 36.8 / 100 (SELL) | 45.1 / 100 (HOLD) | Higher Composite | NVCT |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full VIVS vs NVCT Buy Guide
VIVS
BREAKDOWN
73d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
NVCT
BREAKDOWN
101d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
17th %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither VIVS nor NVCT registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.